Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

AMY SUSAN PALLER

Allopathic & Osteopathic Physicians Pediatrics

NPI
1861452815
CMS profile
311623
Location
CHICAGO, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$226,261.75

60 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
SANOFI-AVENTIS U.S. LLC $52,835.50 10
GENZYME CORPORATION $42,156.00 9
PFIZER INC. $26,000.00 4
LEO Pharma Inc. $23,000.00 4
Novartis Pharmaceuticals Corporation $17,139.75 7
LEO Pharma AS $14,525.00 5
UCB SA $8,300.00 2
E.R. Squibb & Sons, L.L.C. $6,363.00 1
Eli Lilly and Company $5,906.25 2
AbbVie Inc. $5,600.00 3
Incyte Corporation $4,900.00 2
Regeneron Healthcare Solutions, Inc. $4,515.00 2
Regeneron Pharmaceuticals, Inc. $4,041.25 3
Almirall LLC $3,200.00 1
Amryt Pharma Holdings Ltd $2,440.00 1
BioCryst US Sales Co., LLC $2,250.00 1
Boehringer Ingelheim International GmbH $1,440.00 1
Amgen Inc. $850.00 1
Acrotech Biopharma LLC $800.00 1

Page 2 of 2; records 51–60 of 60 matching records. This page contains 10 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

AMY SUSAN PALLER

NPI 1861452815 · CMS profile ID 311623

Allopathic & Osteopathic Physicians / Pediatrics

CHICAGO, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–60 of 60 matching records. This page contains 10 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1861452815?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
AMY SUSAN PALLER, NPI 1861452815, CMS profile ID 311623. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–60 of 60 matching records. This page contains 10 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1861452815?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). AMY SUSAN PALLER, NPI 1861452815, CMS profile ID 311623. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–60 of 60 matching records. This page contains 10 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1861452815?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
AMY SUSAN PALLER, NPI 1861452815, CMS profile ID 311623, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–60 of 60 matching records. This page contains 10 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1861452815?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

60 matching records · $226,261.75 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 60 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–60 of 60.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AbbVie Inc. $2,400.0003/31/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795481599 CMS
GENZYME CORPORATION $10,362.0003/29/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843503851 CMS
Novartis Pharmaceuticals Corporation $2,160.0003/24/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813138083 CMS
LEO Pharma AS $830.0002/24/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842126355 CMS
Novartis Pharmaceuticals Corporation $2,160.0002/24/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813138087 CMS
PFIZER INC. $7,600.0002/22/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833390855 CMS
SANOFI-AVENTIS U.S. LLC $6,123.0001/25/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843503769 CMS
LEO Pharma Inc. $1,400.0001/22/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842239033 CMS
AbbVie Inc. $800.0001/06/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795481593 CMS
LEO Pharma AS $3,320.0001/04/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842126335 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $168,212.03 106
PY2020 $226,057.09 101
PY2021 $226,261.75 60
PY2022 $193,290.89 86
PY2023 $116,144.13 77
PY2024 $150,573.01 83
PY2025 $126,121.47 76

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $61,064.95 56
PY2025 Principal investigator $607,010.69 41
PY2024 Recipient $59,361.14 68
PY2024 Principal investigator $1,012,472.05 77
PY2023 Recipient $51,367.44 81
PY2023 Principal investigator $818,187.43 93
PY2022 Recipient $54,204.43 75
PY2022 Principal investigator $707,256.38 68
PY2021 Recipient $52,404.61 80
PY2021 Principal investigator $556,805.78 78
PY2020 Recipient $25,390.18 30
PY2020 Principal investigator $690,260.11 53
PY2019 Recipient $39,056.51 44
PY2019 Principal investigator $1,353,895.80 62

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

97 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Organon Llc $2,918.71 12/22/2025 Non-covered Recipient Entity
Northwestern University-M.S.S
Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects No dispute reported 06/30/2026 1173042830
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,053.90 12/04/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184269437
Principal investigator 1 Organon Llc $3,661.68 12/01/2025 Non-covered Recipient Entity
Northwestern University-M.S.S
Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects No dispute reported 06/30/2026 1173042826
Recipient Regeneron Pharmaceuticals, Inc. $375.00 12/01/2025 Covered Recipient Physician DUPIXENT CLINICAL DEVELOPMENT PROGRAM No dispute reported 06/30/2026 1184121101
Recipient Regeneron Pharmaceuticals, Inc. $275.00 12/01/2025 Covered Recipient Physician DUPIXENT CLINICAL DEVELOPMENT PROGRAM No dispute reported 06/30/2026 1184121103
Recipient Regeneron Pharmaceuticals, Inc. $416.67 12/01/2025 Covered Recipient Physician DUPIXENT CLINICAL DEVELOPMENT PROGRAM No dispute reported 06/30/2026 1184121105
Recipient Regeneron Pharmaceuticals, Inc. $275.00 12/01/2025 Covered Recipient Physician DUPIXENT CLINICAL DEVELOPMENT PROGRAM No dispute reported 06/30/2026 1184121107
Recipient Regeneron Pharmaceuticals, Inc. $868.68 12/01/2025 Covered Recipient Physician DUPIXENT CLINICAL DEVELOPMENT PROGRAM No dispute reported 06/30/2026 1184121109
Recipient Regeneron Pharmaceuticals, Inc. $340.91 12/01/2025 Covered Recipient Physician DUPIXENT CLINICAL DEVELOPMENT PROGRAM No dispute reported 06/30/2026 1184121111
Principal investigator 1 Janssen Research & Development, LLC $8,368.00 11/17/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A Study to Evaluate the Efficacy Safety and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants No dispute reported 06/30/2026 1175359496
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $386.75 11/07/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184257851
Recipient Regeneron Pharmaceuticals, Inc. $1,135.00 11/01/2025 Covered Recipient Physician DUPIXENT CLINICAL DEVELOPMENT PROGRAM No dispute reported 06/30/2026 1184121095
Recipient Regeneron Pharmaceuticals, Inc. $928.64 11/01/2025 Covered Recipient Physician DUPIXENT CLINICAL DEVELOPMENT PROGRAM No dispute reported 06/30/2026 1184121097
Recipient Regeneron Pharmaceuticals, Inc. $1,135.00 11/01/2025 Covered Recipient Physician DUPIXENT CLINICAL DEVELOPMENT PROGRAM No dispute reported 06/30/2026 1184121099
Principal investigator 1 Organon Llc $6,614.87 10/28/2025 Non-covered Recipient Entity
Northwestern University-M.S.S
Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects No dispute reported 06/30/2026 1173042820
Recipient GENZYME CORPORATION $500.00 10/24/2025 Covered Recipient Physician Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226111805
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,082.20 10/23/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184252780
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,495.91 10/03/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184244801
Recipient ABBVIE INC. $1,800.00 10/01/2025 Covered Recipient Physician A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, and Tolerability of Upadacitinib in Pediatric Subjects 6 to <12 Years Old with Non-Segmental Vitiligo Who Are Eligible for Systemic Therapy No dispute reported 06/30/2026 1202400381
Recipient Regeneron Pharmaceuticals, Inc. $711.87 10/01/2025 Covered Recipient Physician DUPIXENT CLINICAL DEVELOPMENT PROGRAM No dispute reported 06/30/2026 1184121085
Recipient Regeneron Pharmaceuticals, Inc. $923.78 10/01/2025 Covered Recipient Physician DUPIXENT CLINICAL DEVELOPMENT PROGRAM No dispute reported 06/30/2026 1184121087
Recipient Regeneron Pharmaceuticals, Inc. $389.00 10/01/2025 Covered Recipient Physician DUPIXENT CLINICAL DEVELOPMENT PROGRAM No dispute reported 06/30/2026 1184121089
Recipient Regeneron Pharmaceuticals, Inc. $3,426.80 10/01/2025 Covered Recipient Physician DUPIXENT CLINICAL DEVELOPMENT PROGRAM No dispute reported 06/30/2026 1184121091
Recipient Regeneron Pharmaceuticals, Inc. $375.00 10/01/2025 Covered Recipient Physician DUPIXENT CLINICAL DEVELOPMENT PROGRAM No dispute reported 06/30/2026 1184121093
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,168.00 09/30/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
REPURPOSING DUPILUMAB FOR MANAGEMENT OF PRURITIC GENETIC INFLAMMATORY SKIN DISORDERS: A SINGLE-SITE PILOT STUDY No dispute reported 06/30/2026 1184244421
Recipient GENZYME CORPORATION $500.00 09/17/2025 Covered Recipient Physician Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226111764
Recipient GENZYME CORPORATION $500.00 09/17/2025 Covered Recipient Physician Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226111770
Principal investigator 1 Galderma Laboratories, L.P. $1,785.00 09/02/2025 Non-covered Recipient Entity
PALLER
A Multicenter, Open-Label, Single-Group Clinical Trial to Assess the Pharmacokinetics, Safety and Efficacy of Nemolizumab (CD14152) in Pediatric Subjects (aged 2 to 11 years) with Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 1234516526
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $110.50 08/21/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184229795
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $331.50 08/07/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184226297
Principal investigator 1 ABBVIE INC. $54,470.56 08/06/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202502921
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $40,549.84 08/05/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
USING DUPILUMAB TO IMPROVE CIRCADIAN FUNCTION SLEEP AND PRURITUS IN CHILDREN WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184223602
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $331.50 07/31/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184222950
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $442.00 07/17/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184217224
Principal investigator 1 Eli Lilly and Company $18,592.00 07/15/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A PHASE 3, MULTICENTER, LONG-TERM EXTENSION STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PARTICIPANTS 6 MONTHS TO <18 YEARS OF AGE WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1187886452
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $157,046.26 07/09/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
REPURPOSING DUPILUMAB FOR MANAGEMENT OF PRURITIC GENETIC INFLAMMATORY SKIN DISORDERS: A SINGLE-SITE PILOT STUDY No dispute reported 06/30/2026 1184213371
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $723.08 07/04/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184212969
Recipient GENZYME CORPORATION $500.00 06/26/2025 Covered Recipient Physician Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226111759
Recipient GENZYME CORPORATION $250.00 06/26/2025 Covered Recipient Physician Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226111789
Recipient GENZYME CORPORATION $250.00 06/25/2025 Covered Recipient Physician An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients greater than or equal to 6 to less than 18 Years of Age With Atopic Dermatitis No dispute reported 06/30/2026 1226111801
Principal investigator 1 Galderma Laboratories, L.P. $1,785.00 06/12/2025 Non-covered Recipient Entity
PALLER
A Multicenter, Open-Label, Single-Group Clinical Trial to Assess the Pharmacokinetics, Safety and Efficacy of Nemolizumab (CD14152) in Pediatric Subjects (aged 2 to 11 years) with Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 1234514905
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $165.75 06/12/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184206487
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $805.95 06/05/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184204319
Recipient Regeneron Pharmaceuticals, Inc. $640.68 06/01/2025 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB ADMINISTERED CONCOMITANTLY WITH TOPICAL CORTICOSTEROIDS IN PATIENTS, >=6 YEARS TO <12 YEARS OF AGE, WITH SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184121081
Recipient Regeneron Pharmaceuticals, Inc. $1,459.29 06/01/2025 Covered Recipient Physician AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184121083
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $861.20 05/28/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184198993
Recipient GENZYME CORPORATION $1,250.00 05/27/2025 Covered Recipient Physician An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients greater than or equal to 6 to less than 18 Years of Age With Atopic Dermatitis No dispute reported 06/30/2026 1226111782
Principal investigator 1 Organon Llc $10,312.80 05/26/2025 Non-covered Recipient Entity
Northwestern University-M.S.S
Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects No dispute reported 06/30/2026 1173042012
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $221.00 05/15/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184194839
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $165.75 05/15/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184194841
Recipient Regeneron Pharmaceuticals, Inc. $851.25 05/01/2025 Covered Recipient Physician AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184121071
Recipient Regeneron Pharmaceuticals, Inc. $333.32 05/01/2025 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB ADMINISTERED CONCOMITANTLY WITH TOPICAL CORTICOSTEROIDS IN PATIENTS, >=6 YEARS TO <12 YEARS OF AGE, WITH SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184121073
Recipient Regeneron Pharmaceuticals, Inc. $535.71 05/01/2025 Covered Recipient Physician NEUROPSYCHOLOGIC ASSESSMENTS OF DUPILUMAB-TREATED ADOLESCENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184121075
Recipient Regeneron Pharmaceuticals, Inc. $375.00 05/01/2025 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB ADMINISTERED CONCOMITANTLY WITH TOPICAL CORTICOSTEROIDS IN PATIENTS, >=6 YEARS TO <12 YEARS OF AGE, WITH SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184121077
Recipient Regeneron Pharmaceuticals, Inc. $246.65 05/01/2025 Covered Recipient Physician AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184121079
Principal investigator 1 Eli Lilly and Company $875.54 04/23/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A PHASE 3, MULTICENTER, LONG-TERM EXTENSION STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PARTICIPANTS 6 MONTHS TO <18 YEARS OF AGE WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1187888562
Principal investigator 1 Eli Lilly and Company $78,083.00 04/15/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS (PK) OF BARICITINIB IN CHILDREN FROM 6 YEARS TO LESS THAN 18 YEARS OF AGE WITH ALOPECIA AREATA No dispute reported 06/30/2026 1187886456
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,303.20 04/15/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184183248
Recipient Regeneron Pharmaceuticals, Inc. $2,499.00 04/01/2025 Covered Recipient Physician NEUROPSYCHOLOGIC ASSESSMENTS OF DUPILUMAB-TREATED ADOLESCENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184121065
Recipient Regeneron Pharmaceuticals, Inc. $668.22 04/01/2025 Covered Recipient Physician AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184121067
Recipient Regeneron Pharmaceuticals, Inc. $741.07 04/01/2025 Covered Recipient Physician A PHASE 2/3 STUDY INVESTIGATING THE PHARMACOKINETICS, SAFETY, AND EFFICACY OF DUPILUMAB IN PATIENTS AGED >=6 MONTHS TO <6 YEARS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184121069
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,394.08 03/19/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184174430
Recipient Amgen Inc. $13,654.66 03/12/2025 Covered Recipient Physician A Phase 3b, Multi Center, Open-label, Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1246637242
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $110.50 03/11/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184170772
Recipient GENZYME CORPORATION $500.00 03/07/2025 Covered Recipient Physician An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients greater than or equal to 6 to less than 18 Years of Age With Atopic Dermatitis No dispute reported 06/30/2026 1226111774
Recipient GENZYME CORPORATION $250.00 03/07/2025 Covered Recipient Physician An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients greater than or equal to 6 to less than 18 Years of Age With Atopic Dermatitis No dispute reported 06/30/2026 1226111795
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,160.66 03/04/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184156636
Recipient Regeneron Pharmaceuticals, Inc. $640.68 03/01/2025 Covered Recipient Physician DUPIXENT CLINICAL DEVELOPMENT PROGRAM No dispute reported 06/30/2026 1184121043
Recipient Regeneron Pharmaceuticals, Inc. $640.68 03/01/2025 Covered Recipient Physician DUPIXENT CLINICAL DEVELOPMENT PROGRAM No dispute reported 06/30/2026 1184121045
Recipient Regeneron Pharmaceuticals, Inc. $640.68 03/01/2025 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB ADMINISTERED CONCOMITANTLY WITH TOPICAL CORTICOSTEROIDS IN PATIENTS, >=6 YEARS TO <12 YEARS OF AGE, WITH SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184121047
Recipient Regeneron Pharmaceuticals, Inc. $670.68 03/01/2025 Covered Recipient Physician AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184121049
Recipient Regeneron Pharmaceuticals, Inc. $750.00 03/01/2025 Covered Recipient Physician DUPIXENT CLINICAL DEVELOPMENT PROGRAM No dispute reported 06/30/2026 1184121051
Recipient Regeneron Pharmaceuticals, Inc. $190.38 03/01/2025 Covered Recipient Physician AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184121053
Recipient Regeneron Pharmaceuticals, Inc. $340.91 03/01/2025 Covered Recipient Physician AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184121055
Recipient Regeneron Pharmaceuticals, Inc. $450.00 03/01/2025 Covered Recipient Physician AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184121057
Recipient Regeneron Pharmaceuticals, Inc. $247.50 03/01/2025 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB ADMINISTERED CONCOMITANTLY WITH TOPICAL CORTICOSTEROIDS IN PATIENTS, >=6 YEARS TO <12 YEARS OF AGE, WITH SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184121059
Recipient Regeneron Pharmaceuticals, Inc. $1,021.50 03/01/2025 Covered Recipient Physician A PHASE 2/3 STUDY INVESTIGATING THE PHARMACOKINETICS, SAFETY, AND EFFICACY OF DUPILUMAB IN PATIENTS AGED >=6 MONTHS TO <6 YEARS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184121061
Recipient Regeneron Pharmaceuticals, Inc. $928.64 03/01/2025 Covered Recipient Physician AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184121063
Principal investigator 1 Eli Lilly and Company $1,569.42 02/25/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO ASSESS THE EFFICACY, SAFETY AND PHARMACOKINETICS OF LEBRIKIZUMAB COMPARED TO PLACEBO IN PARTICIPANTS 6 MONTHS TO <18 YEARS OF AGE WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1187890136
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,050.16 02/25/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184155490
Recipient ABBVIE INC. $13,895.39 02/22/2025 Covered Recipient Physician A Phase 3, Open-label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202400377
Recipient ABBVIE INC. $47.67 02/21/2025 Covered Recipient Physician A Phase 3, Open-label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202400362
Recipient ABBVIE INC. $15.41 02/21/2025 Covered Recipient Physician A Phase 3, Open-label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202400365
Recipient ABBVIE INC. $245.95 02/21/2025 Covered Recipient Physician A Phase 3, Open-label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202400370
Recipient ABBVIE INC. $15.41 02/21/2025 Covered Recipient Physician A Phase 3, Open-label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202400374
Recipient ABBVIE INC. $52.02 02/20/2025 Covered Recipient Physician A Phase 3, Open-label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202400353
Recipient ABBVIE INC. $245.95 02/20/2025 Covered Recipient Physician A Phase 3, Open-label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202400358
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $165.75 02/18/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184154364
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,823.66 02/11/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184153042
Recipient ABBVIE INC. $29.30 02/07/2025 Covered Recipient Physician A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202400343
Recipient ABBVIE INC. $58.00 02/07/2025 Covered Recipient Physician A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202400346
Recipient ABBVIE INC. $57.00 02/07/2025 Covered Recipient Physician A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202400350
Principal investigator 1 Organon Llc $5,809.00 02/03/2025 Non-covered Recipient Entity
Northwestern University-M.S.S
Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects No dispute reported 06/30/2026 1173041986
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $331.50 01/17/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184148217
Principal investigator 1 UCB SA $36,562.00 01/15/2025 Non-covered Recipient Entity
Northwestern University
MULTICENTER, RANDOMIZED, PARALLEL GROUP, DOUBLE BLIND, PLACEBO-CONTROLLED (12 17 YEARS) INCLUDING A SINGLE OPEN LABEL ARM (6 11 YEARS) STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF CERTOLIZUMAB PEGOL (CZP) IN PEDIATRIC STUDY PARTICIPANTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS (PSO) No dispute reported 06/30/2026 1246657065
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $276.25 01/07/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184146022
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $157,046.26 01/03/2025 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
REPURPOSING DUPILUMAB FOR MANAGEMENT OF PRURITIC GENETIC INFLAMMATORY SKIN DISORDERS: A SINGLE-SITE PILOT STUDY No dispute reported 06/30/2026 1184144782